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Background-—We evaluated lipoprotein-associated phospholipase A2 (Lp-PLA2) activity in patients with stable coronary heart
disease before and during treatment with darapladib, a selective Lp-PLA2 inhibitor, in relation to outcomes and the effects of
darapladib in the STABILITY trial.
Methods and Results-—Plasma Lp-PLA2 activity was determined at baseline (n=14 500); at 1 month (n=13 709); serially (n=100)
at 3, 6, and 18 months; and at the end of treatment. Adjusted Cox regression models evaluated associations between Lp-PLA2
activity levels and outcomes. At baseline, the median Lp-PLA2 level was 172.4 lmol/min per liter (interquartile range 143.1–204.2
lmol/min per liter). Comparing the highest and lowest Lp-PLA2 quartile groups, the hazard ratios were 1.50 (95% CI 1.23–1.82) for
the primary composite end point (cardiovascular death, myocardial infarction, or stroke), 1.95 (95% CI 1.29–2.93) for
hospitalization for heart failure, 1.42 (1.07–1.89) for cardiovascular death, and 1.37 (1.03–1.81) for myocardial infarction after
adjustment for baseline characteristics, standard laboratory variables, and other prognostic biomarkers. Treatment with darapladib
led to a 65% persistent reduction in median Lp-PLA2 activity. There were no associations between on-treatment Lp-PLA2 activity
or changes of Lp-PLA2 activity and outcomes, and there were no signiﬁcant interactions between baseline and on-treatment Lp-
PLA2 activity or changes in Lp-PLA2 activity levels and the effects of darapladib on outcomes.
Conclusions-—Although high Lp-PLA2 activity was associated with increased risk of cardiovascular events, pharmacological
lowering of Lp-PLA2 activity by 65% did not signiﬁcantly reduce cardiovascular events in patients with stable coronary heart
disease, regardless of the baseline level or the magnitude of change of Lp-PLA2 activity.
Clinical Trial Registration-—URL: https://www.clinicaltrials.gov. Unique identiﬁer: NCT00799903. ( J Am Heart Assoc. 2016;5:
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I nﬂammatory activity is an integral component of thedevelopment of atherosclerosis and its complications.1
Biomarkers indicating myocardial dysfunction (eg, troponin,
natriuretic peptides), renal dysfunction (eg, cystatin C), and
inﬂammatory activity (eg, C-reactive protein) are risk
indicators of future cardiovascular events in healthy persons
and in patients with established coronary heart disease
(CHD).2–5 Higher levels of lipoprotein-associated phospholi-
pase A2 (Lp-PLA2) activity have also been associated with an
increased risk of coronary events in healthy elderly persons
Table 1. Demographics, Baseline Characteristics, and Biomarker Levels in Relation to Quartile Groups of Baseline Lp-PLA2 Activity
Variables
Baseline Lp-PLA2 Activity
P Value
P Value
for Trend
Q1 (<143.1)
n=3617
Q2 (143.1–172.4)
n=3631
Q3 (172.4–204.2)
n=3615
Q4 (≥204.2)
n=3637
Lp-PLA2, lmol/min/L 125 (108–135) 158 (151–166) 187 (180–195) 230 (216–253) <0.0001 <0.0001
Assigned treatment
Placebo 1817 (50.2) 1766 (48.6) 1779 (49.2) 1859 (51.1) 0.1544 0.4342
Darapladib 1800 (49.8) 1865 (51.4) 1836 (50.8) 1778 (48.9)
Age, y 65 (60–71)* 65 (60–71) 65 (59–71) 64 (57–71) <0.0001 <0.0001
Sex, male 2490 (68.8) 2916 (80.3) 3127 (86.5) 3291 (90.5) <0.0001 <0.0001
Geographic region <0.0001 <0.0001
Asia–Pacific 821 (22.7) 602 (16.6) 534 (14.8) 609 (16.7)
Eastern Europe 712 (19.7) 826 (22.7) 922 (25.5) 958 (26.3)
North America 873 (24.1) 910 (25.1) 961 (26.6) 1061 (29.2)
South America 207 (5.7) 204 (5.6) 231 (6.4) 226 (6.2)
Western Europe 1004 (27.8) 1089 (30.0) 967 (26.7) 783 (21.5)
Weight, kg 79 (68–91) 83 (73–94) 84 (74–95) 85 (74–96) <0.0001 <0.0001
Current smoker 466 (12.9) 555 (15.3) 677 (18.7) 926 (25.5) <0.0001 <0.0001
Hypertension 2627 (72.6) 2608 (71.8) 2569 (71.1) 2560 (70.4) 0.1275 0.0311
Diabetes mellitus 1678 (46.4) 1459 (40.2) 1272 (35.2) 1185 (32.6) <0.0001 <0.0001
Statin at randomization 3575 (98.8) 3577 (98.5) 3508 (97.0) 3439 (94.6) <0.0001 <0.0001
High-intensity statin 268 (7.4) 270 (7.4) 242 (6.7) 227 (6.2) 0.1271 0.0201
Prior myocardial infarction 2079 (57.5) 2146 (59.1) 2167 (59.9) 2197 (60.4) 0.0583 0.0018
Prior PCI or CABG 2731 (75.5) 2735 (75.3) 2677 (74.1) 2661 (73.2) 0.0715 0.0035
Polyvascular disease 491 (13.6) 535 (14.7) 529 (14.6) 649 (17.8) <0.0001 <0.0001
LDL cholesterol, mmol/L 1.7 (1.3–2.1) 1.9 (1.6–2.3) 2.2 (1.8–2.7) 2.6 (2.1–3.3) <0.0001 <0.0001
HDL cholesterol, mmol/L 1.3 (1.1–1.5) 1.2 (1.0–1.4) 1.2 (1.0–1.4) 1.1 (0.9–1.3) <0.0001 <0.0001
Triglycerides, mmol/L 1.3 (1.0–1.8) 1.5 (1.1–2.0) 1.6 (1.1–2.2) 1.7 (1.3–2.4) <0.0001 <0.0001
Hemoglobin, g/L 138 (129–146) 142 (133–151) 145 (137–153) 148 (139–156) <0.0001 <0.0001
eGFR, mL/min† 75 (62–87) 74 (61–86) 74 (62–86) 74 (61–87) 0.5690 0.9025
C-reactive protein, mg/L 2.8 (1.3–3.1) 2.8 (1.4–3.1) 2.8 (1.5–3.2) 3.0 (1.5–3.4) <0.0001 <0.0001
Interleukin 6, ng/L 1.2 (0.6–2.9) 1.3 (0.6–2.9) 1.3 (0.7–3.1) 1.6 (0.8–3.6) <0.0001 <0.0001
High-sensitivity troponin T, ng/L 9.0 (5.9–13.6) 9.4 (6.4–14.1) 9.4 (6.3–14.2) 9.4 (6.2–15.0) <0.0001 <0.0001
NT-proBNP, ng/L 174 (85–372) 181 (87–386) 186 (81–361) 174 (78–402) 0.0762 0.5699
Cystatin C, mg/L 1.0 (0.9–1.2) 1.0 (0.9–1.2) 1.0 (0.9–1.2) 1.0 (0.9–1.2) <0.0001 <0.0001
GDF-15, ng/L 1280 (923–1824) 1250 (902–1798) 1216 (905–1746) 1266 (927–1821) 0.0003 0.0913
Categorical variables are shown as number (percentage); continuous variables are presented as median (interquartile range). CABG indicates coronary artery bypass grafting; eGFR,
estimated glomerular ﬁltration rate; GDF-15, growth differentiation factor 15; HDL, high-density lipoprotein; LDL, low-density lipoprotein; Lp-PLA2, lipoprotein-associated phospholipase A2;
NT-proBNP, N-terminal proB-type natriuretic peptide; PCI, percutaneous coronary intervention; Q, quartile.
†eGFR was estimated using the Chronic Kidney Disease Epidemiology Collaboration formula.
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and in patients with stable CHD.6–9 There is some evidence
that Lp-PLA2 might be part of the atherosclerotic process and
may contribute to plaque destabilization through inﬂammatory
activity in the atherosclerotic lesions.10–12 Consequently, it is
important to further evaluate the independent prognostic
value of Lp-PLA2 activity as a risk marker for individual
nonfatal and fatal cardiovascular events in large long-term
prospective studies of patients with CHD in addition to
considering information provided by other prognostic
biomarkers.
Darapladib is a selective Lp-PLA2 inhibitor
13 that reduces
Lp-PLA2 activity in plasma
14 and in the atherosclerotic
plaque.15,16 Experiments in hypercholesterolemic diabetic
swine17 and in an angiographic and intravascular ultrasound
study in patients18 showed that darapladib prevented pro-
gression of the necrotic core, assumed to be the vulnerable
component of atherosclerotic lesions. In the present STabi-
lization of Atherosclerotic plaque By Initiation of darapLadIb
TherapY (STABILITY) trial (ClinicalTrials.gov identiﬁer
NCT00799903), darapladib 160 mg daily did not signiﬁcantly
reduce the primary composite end point of cardiovascular
death, myocardial infarction (MI), or stroke in patients with
stable CHD (hazard ratio [HR] 0.94, 95% CI 0.85–1.03,
P=0.20) but nominally reduced the rate of the secondary end
point, major coronary events (coronary death, MI, or urgent
coronary revascularization; HR 0.90, 95% CI 0.82–1.00,
P=0.045).19 The present predeﬁned ancillary study evaluated
the independent prognostic value of baseline Lp-PLA2 activity
concerning cardiovascular events, the reduction of Lp-PLA2
activity by darapladib, and the associations between baseline
and changes in Lp-PLA2 activity and clinical outcomes.
Methods
Trial Design, Patients, Treatments, and Follow-up
The STABILITY trial was a prospective double-blind random-
ized trial evaluating the efﬁcacy and safety of darapladib
160 mg, a speciﬁc inhibitor of Lp-PLA2, compared with
placebo concerning cardiovascular outcomes in patients with
stable CHD.19 In brief, the study randomized 15 828 patients
from 39 countries with stable CHD, deﬁned as prior MI, prior
coronary revascularization, or multivessel CHD conﬁrmed by
coronary angiography. Patients also had to meet at least 1 of
the following cardiovascular risk criteria: age ≥60 years;
diabetes mellitus requiring pharmacotherapy; high-density
lipoprotein cholesterol <1.03 mmol/L; current or previous
smoker, deﬁned as ≥5 cigarettes per day on average;
signiﬁcant renal dysfunction (estimated glomerular ﬁltration
rate ≥30 and <60 mL/min per 1.73 m2 or urine albumin:
creatinine ratio of ≥30 mg albumin per gram of creatinine); or
polyvascular disease (CHD and cerebrovascular disease or
CHD and peripheral arterial disease). The patients were
followed with regular outpatient visits for a median of
3.7 years. The primary outcome was the composite of
cardiovascular death, nonfatal MI, or nonfatal stroke.
Secondary outcomes were the composites of major coronary
events (ie, fatal and nonfatal MI, death from CHD, or urgent
coronary revascularization for myocardial ischemia) and the
Table 2. Multivariable Analysis of Demographics, Baseline
Characteristics and Biomarkers Signiﬁcantly Associated With
Baseline Lp-PLA2 Activity
Background
Characteristic
Adjusted
Difference in
Mean* 95% CI* P Value
Western Europe vs
North America
19.81 (21.58; 18.03) <0.0001
Eastern Europe vs
North America
17.09 (18.97; 15.21) <0.0001
Asia–Pacific vs
North America
16.42 (18.48; 14.36) <0.0001
South America vs
North America
14.91 (17.81; 12.02) <0.0001
Female vs male 15.69 (17.60; 13.77) <0.0001
Diabetes mellitus 6.640 (8.092; 5.188) <0.0001
HDL cholesterol,
0.1 mmol/L
increase
4.333 (4.554; 4.113) <0.0001
Diagnosis of
hypertension
2.066 (3.503; 0.6295) 0.0048
Body mass index,
1 kg/m2 increase
0.218 (0.361; 0.074) 0.0030
Triglycerides,
0.1 mmol/L
increase
0.071 (0.139; 0.003) 0.0389
GDF-15, 10%
increase
0.401 (0.252; 0.551) <0.0001
Hemoglobin, 10 g/L
increase
0.589 (0.536; 0.641) <0.0001
Age, 10-year
increase
0.908 (0.005; 1.812) 0.0489
Cystatin C, 10%
increase
1.159 (0.771; 1.547) <0.0001
Polyvascular
disease
1.919 (0.169; 3.671) 0.0317
Current smoker vs
never smoked
2.094 (0.049; 4.139) 0.0447
LDL cholesterol,
0.1 mmol/L
increase
3.118 (3.040; 3.196) <0.0001
GDF-15 indicates growth differentiation factor 15; HDL, high-density lipoprotein; LDL,
low-density lipoprotein; Lp-PLA2, lipoprotein-associated phospholipase A2.
*Mean and 95% CI for adjusted difference in mean Lp-PLA2 activity level estimated in
relation to the respective change in each background characteristic.
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composite of total coronary events, which also included all
coronary revascularizations. Additional secondary end points
were the individual components of the primary composite end
point, hospitalization for heart failure, and all-cause mortality.
Components of cardiovascular death included death from
unknown cause, fatal MI, fatal stroke, complications of a
cardiac procedure, arrhythmia, congestive heart failure or
shock, other vascular cause of death, and sudden death. All
suspected end points were documented and reported by
STABILITY study investigators and were adjudicated by an
independent clinical events committee. All participants pro-
vided informed consent, and the study was approved by the
relevant institutional review committee in each participating
country.
Samples and Biochemical Methods
Blood samples were obtained from the majority of patients at
baseline and 242 hours after the last intake of study drug at
months 1, 3, 6, and 18, and at the end of treatment. Plasma
aliquots were stored in central repositories at 70°C until
biochemical analysis was performed. Measurements of Lp-
PLA2 activity and other biomarkers were performed in 14 500
patients at baseline for whom samples were available and
suitable for assay. For 13 709 of these patients, Lp-PLA2
activity was also measured after 1 month. In addition, the
change in Lp-PLA2 activity over a longer time period was
evaluated in a random sample of 100 patients with plasma
samples available from all follow-up visits. The sample size of
100 patients was based on the assumption of a mean
difference in percentage change from baseline between
treatment groups in Lp-PLA2 activity of between 25% and
65%, with a common standard deviation of 25%, a 2-sided type
I error rate (a level) of 5% and power of 90%. In total, 100
participants were selected with the goal of having 50
participants from each treatment group to describe the
long-term inhibition of Lp-PLA2 activity by the randomized
treatment.
The Lp-PLA2 activity was measured in an automated
enzyme assay system (PLAC Test for Lp-PLA2 Activity;
Figure 1. Quartile groups of baseline Lp-PLA2 activity (in lmol/min per liter) in relation to outcomes by Kaplan–Meier analysis. A, Major
adverse cardiac events (cardiovascular death, myocardial infarction, or stroke). B, Cardiovascular death. Q indicates quartile; Lp-PLA2;
lipoprotein-associated phospholipase A2.
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Diadexus) with a colorimetric substrate that is converted on
hydrolysis by the phospholipase enzyme. The analytical
sensitivity (limit of quantitation) of the assay is 10 lmol/
min per liter. Within-run and within-laboratory variability were
determined by testing 4 human plasma samples and 2
controls with Lp-PLA2 activities ranging from 113 to
315 lmol/min per liter. Samples were assayed in duplicate
twice a day over 20 days and with 3 kit lots using 1
instrument. Total precision coefﬁcients of variation for each
reagent lot and sample were <3%. Several dilution series were
prepared from plasma samples with known high and low Lp-
PLA2 activity levels and were tested with 3 kit lots. Linearity
with a deviation of ≤10% was demonstrated from 10 to
382 lmol/min per liter, which is considered the measuring
range of the assay. The Lp-PLA2 activity measurements were
performed by the manufacturer (Diadexus) on samples
blinded for study treatment. The levels of high-sensitivity
cardiac troponin T, N-terminal proB-type natriuretic peptide,
growth differentiation factor 15 (precommercial assay),20 and
cystatin C were determined by electrochemiluminiscence
immunoassays using a Cobas Analytics e601 system (Roche
Diagnostics), performed at the Uppsala Clinical Research
Center Laboratory at Uppsala University in Sweden. High-
sensitivity C-reactive protein was analyzed using the
CardioPhase high-sensitivity C-reactive protein (Dade Behring)
2-site particle-enhanced immunonephelometry sandwich
assay. The routine biochemical analyses and high-sensitivity
C-reactive protein assay were performed at a central labora-
tory with standardized methods (Quest Diagnostics Clinical
Laboratories, Inc).
A
Figure 2. Baseline Lp-PLA2 activity (lmol/min per liter) quartile groups in relation to outcomes in (A) all patients,
(B) in women, and (C) in men, adjusted for demographics, baseline characteristics, routine biochemical variables,
and prognostic biomarkers. The x-axis presents a logarithmic scale. MACE indicates CV death, MI, or stroke; MCE
indicates coronary heart disease death, MI, or urgent coronary revascularization. Event rates are Kaplan–Meier
rates. Adjustment variables: randomized treatment, geographic region, age, sex, body mass index, current smoking,
hypertension, diabetes mellitus, prior MI, prior coronary revascularization, multivessel coronary heart disease,
polyvascular disease, signiﬁcant renal dysfunction, routine biochemical variables (hemoglobin, white blood cell
count, estimated glomerular ﬁltration rate [Chronic Kidney Disease Epidemiology Collaboration], low-density
lipoprotein cholesterol, high-density lipoprotein cholesterol, and triglycerides), and prognostic biomarkers (N-
terminal proB-type natriuretic peptide, high-sensitivity cardiac troponin T, cystatin C, high-sensitivity C-reactive
protein, and interleukin 6). CV indicates cardiovascular; HR, hazard ratio; Lp-PLA2, lipoprotein-associated
phospholipase A2; MACE, major adverse cardiac events; MCE, major coronary events; MI, myocardial infarction; Q,
quartile.
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Figure 2. Continued
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Statistics
Lp-PLA2 activity at baseline
Demographics and other baseline characteristics were sum-
marized by quartile group of the baseline Lp-PLA2 activity level.
The univariable relationships between Lp-PLA2 activity and
background variables were evaluated using the chi-square and
Kruskal–Wallis tests for categorical and continuous variables,
respectively. Multivariable analyses were used to evaluate the
independent associations between baseline Lp-PLA2 activity
and other variables, using linear regression models in which
continuous variables were included as linear or log-trans-
formed variables, as appropriate. Baseline Lp-PLA2 activity as a
predictor of outcomes was evaluated using Kaplan–Meier
estimates of the cumulative risk to the ﬁrst occurrence of an
event for the Lp-PLA2 quartile groups. The independent
associations between baseline Lp-PLA2 activity levels and
outcomes were evaluated using adjusted Cox regression
models in which the HR and 95% CI were calculated using the
lowest quartile group of Lp-PLA2 activity (quartile 1) as the
reference and performing a trend analysis across quartile
groups. The predeﬁned adjustment variables for the statistical
analyses were randomized treatment, geographic region, age,
sex, body mass index, current smoking, hypertension, diabetes
mellitus, prior MI, prior coronary revascularization, multivessel
CHD, polyvascular disease, signiﬁcant renal dysfunction, levels
of standard biomarkers (hemoglobin, white blood cell count,
estimated glomerular ﬁltration rate [Chronic Kidney Disease
Epidemiology Collaboration], low-density lipoprotein choles-
terol, high-density lipoprotein cholesterol, and triglycerides),
and levels of prognostic biomarkers (high-sensitivity cardiac
troponin T, N-terminal proB-type natriuretic peptide, growth
differentiation factor 15, high-sensitivity C-reactive protein,
interleukin 6), which were entered as quartiles after log
transformation. A Cox proportional hazards model with
treatment group (darapladib or placebo), baseline Lp-PLA2
activity categorized by quartile group, and treatment group Lp-
PLA2 activity interaction as independent variables was used to
test whether the treatment effect differed in relation to Lp-
PLA2 activity level. The relevance of the Lp-PLA2 activity
interacting with the effect of treatment was evaluated based
on the signiﬁcance of interaction statistics. Data were handled
by complete-case analyses with no imputation for missing
values. No correction for multiplicity was performed. The
analyses of associations between the Lp-PLA2 activity and
baseline characteristics, other biomarkers and outcomes, and
changes of Lp-PLA2 activity over time were prespeciﬁed in the
statistical analysis plans.
Lp-PLA2 activity over time
The HRs and P values for the association of changes in Lp-
PLA2 activity after 1 month and clinical outcomes were
estimated using a Cox proportional hazards regression model
with baseline Lp-PLA2 activity and change from baseline to
month 1 in Lp-PLA2 activity as the covariate, stratiﬁed by
treatment. In the 100-participant cohort, Lp-PLA2 activity over
time was characterized using the generalized estimating
equations model with participants ﬁtted as a repeated effect,
and it included the following terms: treatment, visit, baseline
Lp-PLA2 activity, treatment by visit, and baseline by visit
Table 3. C-Indices and Reclassiﬁcation Statistics When Adding Information on the Lp-PLA2 Activity Level to the Full Model of
Baseline Characteristics and Other Biomarkers
Outcome
C-Index (95% CI)
Lp-PLA2
C-Index (95% CI)
+Lp-PLA2
Event
NRI
Nonevent
NRI NRI
MACE 0.675 (0.659–0.691) 0.678 (0.662–0.694) 0.074 0.248 0.175
MCE 0.658 (0.641–0.674) 0.659 (0.643–0.676) 0.074 0.238 0.164
Cardiovascular death 0.756 (0.733–0.780) 0.757 (0.734–0.781) 0.046 0.237 0.191
MI 0.665 (0.642–0.687) 0.667 (0.645–0.689) 0.099 0.239 0.140
Stroke 0.680 (0.646–0.714) 0.686 (0.652–0.720) 0.084 0.050 0.134
Heart failure 0.832 (0.804–0.860) 0.833 (0.805–0.861) 0.167 0.081 0.249
Non-cardiovascular death 0.740 (0.708–0.772) 0.743 (0.711–0.775) 0.051 0.125 0.176
Cancer death 0.757 (0.716–0.798) 0.758 (0.717–0.799) 0.194 0.029 0.165
Total death 0.732 (0.714–0.751) 0.735 (0.716–0.753) 0.005 0.207 0.202
The full model contained the following data: randomized treatment, geographic region, age, sex, body mass index, current smoking, hypertension, diabetes mellitus, prior myocardial
infarction, prior coronary revascularization, multivessel coronary heart disease, polyvascular disease, signiﬁcant renal dysfunction, routine biochemical variables (hemoglobin, white blood
cell count, estimated glomerular ﬁltration rate [Chronic Kidney Disease Epidemiology Collaboration], low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and
triglycerides), and prognostic biomarkers (N-terminal proB-type natriuretic peptide, high-sensitivity cardiac troponin T, cystatin C, high-sensitivity C-reactive protein, and interleukin 6).
Lp-PLA2 indicates lipoprotein-associated phospholipase A2; MACE, major adverse cardiac events; MCE, major coronary events; MI, myocardial infarction; NRI, net reclassiﬁcation index.
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interactions. Point estimates, 95% CIs, and P values for the
mean differences between patients treated with darapladib
and placebo at months 1, 3, 6, and 18, and at the end of
treatment were calculated using this generalized estimating
equations model.
Results
For the 14 500 patients with Lp-PLA2 activity measurements,
baseline characteristics were representative of the overall
STABILITY population and balanced between the randomized
treatment groups (Table 1). There were no differences in rates
of outcome events between patients with and without Lp-
PLA2 activity measurements. The distribution of the Lp-PLA2
activity levels did not deviate from normality (median 172
lmol/min per liter [interquartile range 143–204 lmol/min
per liter]). There were statistically signiﬁcant differences for
the majority of the baseline characteristics and levels of other
biomarkers when stratifying patients by baseline Lp-PLA2
quartile groups (Table 1). The following factors showed
independent and relevant associations with higher Lp-PLA2
activity in multivariable analyses: male sex, North American
origin, current smoking, higher low-density lipoprotein choles-
terol level, and lower high-density lipoprotein cholesterol
level. Diabetes mellitus was associated with lower Lp-PLA2
activity (Table 2).
In the present cohort, 661 (4.6%) cardiovascular deaths, 695
(4.8%) MIs, and 280 (1.9%) strokes occurred. Of the 661
cardiovascular deaths, 142 deaths of unknown cause were not
veriﬁed as noncardiovascular and thus were included among
the cardiovascular deaths. In total, there were 1444 (10.0%)
ﬁrst primary outcome events and 1404 (9.7%) major coronary
events. The outcome events were accrued at a stable rate
during follow-up (Figure 1). There was a signiﬁcant difference in
event rates between the highest quartile group of baseline Lp-
PLA2 activity in comparison to the lower 3 quartile groups,
among which no signiﬁcant differences in event rates were
observed (Figures 1 and 2). The higher event rates in the
highest Lp-PLA2 quartile group were observed for all types of
events, namely, the primary composite of cardiovascular death,
MI, or stroke; the secondary composite of major coronary
events; and the individual events cardiovascular death, MI,
stroke, hospitalization for heart failure, and cardiovascular and
total mortality. The elevated event rates of all of these events in
the highest Lp-PLA2 quartile group were maintained after
adjusting for baseline characteristics and conventional labora-
tory tests. In addition, after adjustment for the prognostic
biomarkers N-terminal proB-type natriuretic peptide, high-
sensitivity cardiac troponin T, growth differentiation factor 15,
cystatin C, high-sensitivity C-reactive protein, and interleukin 6,
the increased risks of the composite events, hospitalization for
heart failure, cardiovascular death, and total death remained,
Figure 3. Lp-PLA2 activity (lmol/min per liter) over time during treatment with darapladib and placebo in
a subset of 100 patients with available plasma samples for Lp-PLA2 activity measurements until end of
follow-up. Symbols illustrate means and CIs for the respective darapladib (blue) and placebo (red) groups at
baseline; at follow-up visits at 1, 3, 6, and 18 months; and at the EOT visit. D, darapladib; EOT, end of
treatment; Lp-PLA2, lipoprotein-associated phospholipase A2; P, placebo.
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Table 4. Change in Lipoprotein-Associated Phospholipase A2
Activity After 1 Month by Subgroup in Patients Assigned to
Darapladib
Subgroup
Darapladib
n Mean Change
Mean Percentage
Inhibition
Prior MI
Yes 4063 111.8 63.0
No 2773 112.9 64.3
Prior coronary revascularization
Yes 5306 112.7 64.0
No 1815 111.1 62.0
Multivessel CHD
Yes 974 116.7 65.0
No 5862 111.5 63.3
Time from CHD event to randomization
Recent 1628 110.0 63.1
Remote 5229 113.0 63.7
Age ≥60 yr
Yes 5055 112.5 64.5
No 1781 111.7 60.7
Diabetes mellitus requiring pharmaceutical management
Yes 2289 110.4 65.5
No 4547 113.2 62.5
HDL-C <40 mg/dL
Yes 2285 118.9 63.1
No 4549 109.0 63.7
Current/previous smoker
Yes 1344 113.2 60.1
No 5465 112.0 64.4
Significant renal dysfunction
Yes 2068 117.5 66.3
No 4768 110.0 62.3
Polyvascular disease
Yes 1045 115.3 63.9
No 5791 111.7 63.4
No. of additional predictors of cardiovascular risk
1 2376 108.4 62.0
2 2371 112.2 63.3
≥3 2066 117.0 65.5
Race group collapsed
White 5533 112.2 62.6
Nonwhite 1303 112.5 67.2
Region
North America 1756 115.6 64.0
Eastern Europe 1632 109.6 60.4
Western Europe 1833 110.0 63.7
Continued
Table 4. Continued
Subgroup
Darapladib
n Mean Change
Mean Percentage
Inhibition
South America 403 114.0 62.2
Asia–Pacific 1212 114.0 67.2
Group in United States
US 1331 116.0 63.8
Non-US 5505 111.4 63.4
Sex
Male 5623 114.8 63.1
Female 1213 100.8 65.4
Blood pressure
High 3409 113.8 64.3
Target 3425 110.8 62.8
eGFR, mL/min/1.73 m2
<60 937 121.0 67.3
≥60 5888 111.0 62.9
LDL-C, mmol/L
<1.80 2401 97.1 63.3
≥1.80 to <2.50 2723 111.8 63.6
≥2.58 1805 132.5 63.6
Baseline Lp-PLA2 activity
Tertile 1 2273 78.3 61.4
Tertile 2 2342 110.4 64.0
Tertile 3 2221 149.0 65.2
High-sensitivity C-reactive protein, mg/L
<1.0 2516 108.9 63.9
1.0 to 3.0 2359 114.4 63.9
>3.0 1667 115.5 62.9
Family history of CHD
Yes 1750 113.4 63.0
No 5069 111.8 63.7
Body mass index, kg/m2
<25 1380 113.5 66.3
25 to <30 2910 113.6 63.6
≥30 2536 110.1 61.9
Waist/hip ratio
Level 1 851 110.8 65.3
Level 2 1681 113.9 64.9
Level 3 4234 112.1 62.6
Aspirin use
Yes 6293 111.7 63.4
No 568 118.9 64.5
Statin use
Yes 6657 111.7 63.5
No 179 133.9 64.4
Continued
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whereas associations with the individual ischemic events MI or
stroke were somewhat attenuated. After complete adjustment,
the HRs were 1.50 (95% CI 1.23–1.82) for the primary
composite end point, 1.42 (95% CI 1.16–1.74) for major
coronary events, 1.95 (95% CI 1.29–2.93) for hospitalization
for heart failure, 1.42 (95% CI 1.07–1.89) for cardiovascular
death, 1.47 (95% CI 1.17–1.84) for total death, 1.37 (95% CI
1.03–1.81) for MI, and 1.56 (95% CI 1.00–2.44) for stroke
when comparing the highest and lowest Lp-PLA2 quartile
groups (Figure 2A). These ﬁndings were similar in men and
women, without any interaction with sex (Figure 2B and 2C).
The addition of Lp-PLA2 activity levels to the model including all
clinical characteristics, risk factors, and other biomarkers
provided no signiﬁcant change of the c-index and only a modest
improvement of the net reclassiﬁcation index for most events
based on better discrimination of patients without increased
risk (Table 3).
At 1 month, the Lp-PLA2 activity was reduced from a
median of 172 to 57 lmol/min per liter (interquartile range
42–75 lmol/min per liter, mean reduction 112 lmol/min
per liter, mean percentage reduction 64%) in the darapladib
group compared with a median decrease from 173 to
164 lmol/min per liter (interquartile range 136–196 lmol/
min per liter, mean reduction 9 lmol/min per liter, mean
percentage reduction 4%) in the placebo group. Darapladib
treatment produced a persistent 65% relative reduction in
Lp-PLA2 activity from the ﬁrst on-treatment measurement at
1 month until study termination, whereas the placebo group
had no signiﬁcant change in Lp-PLA2 activity (Figure 3). The
changes in Lp-PLA2 activity were consistent in all subgroups
based on clinical characteristics or biomarkers (Table 4).
In the highest Lp-PLA2 quartile group, there was no
signiﬁcant reduction in the primary composite end point of
cardiovascular death, MI, or stroke (HR 0.86, 95% CI 0.72–
1.03), whereas the secondary composite end point of major
coronary events showed a statistically signiﬁcant reduction
(HR 0.82, 95% CI 0.68–0.98); however, there were no
signiﬁcant interactions between quartile groups of baseline
Lp-PLA2 activity and the effects of darapladib (Figures 4 and
5). Finally, there were no signiﬁcant associations between
either the level of Lp-PLA2 activity at 1 month or the reduction
in Lp-PLA2 activity and any of the outcome events in the trial
(Tables 5 through 8).
Discussion
This prespeciﬁed analysis of the STABILITY trial in patients
with stable CHD followed for 3.7 years on a background of
optimal medical therapy veriﬁed that Lp-PLA2 activity is a
marker of overall cardiovascular risk and total mortality in
patients with stable CHD, in accordance with previous
studies.6–9 Dyslipidemia, male sex, current smoking, and
living in the North American region were associated with
higher Lp-PLA2 activity, in agreement with other observa-
tions.21 After adjusting for both baseline characteristics and
other prognostic biomarkers, Lp-PLA2 activity remained a
signiﬁcant marker of composite cardiovascular events, hos-
pitalization for heart failure, and cardiovascular and total
mortality, whereas the associations with new ischemic events
such as MI and stroke were attenuated. The ﬁnding of an
independent association between Lp-PLA2 activity and
composite cardiovascular events is in accordance with most
6–9,22–27 although not all28 previous studies of stable patients
at high risk for or with established CHD. The rather weak
independent association with a raised risk of cardiovascular
events when adjusting for other biomarkers might be a
corollary to the lack of association between Lp-PLA2 activity
and outcomes in patients with acute coronary syndromes hav-
ing pronounced elevations of other prognostic biomarkers.29
Darapladib treatment persistently reduced Lp-PLA2 activity
by 65% in all patient groups, consistent with other
ﬁndings.16,18,29 Reduction in Lp-PLA2 activity was not asso-
ciated with any signiﬁcant effect on the primary composite
outcome of cardiovascular death, MI, or stroke in the
STABILITY trial overall or with any subgroup based on the
Lp-PLA2 activity level at baseline. This lack of effect in the
overall trial and in all Lp-PLA2 activity subgroups is in
agreement with the ﬁndings from the SOLID trial of patients
with recent acute coronary syndromes.29 In addition, in the
present study, there were no signiﬁcant associations between
any outcome and the magnitude of reduction in Lp-PLA2
activity level by darapladib treatment. These accumulated
experiences show that although high Lp-PLA2 activity was
associated with an increased risk of cardiovascular events,
pharmacological lowering of Lp-PLA2 activity was not a useful
Table 4. Continued
Subgroup
Darapladib
n Mean Change
Mean Percentage
Inhibition
Beta blocker use
Yes 5393 111.6 63.2
No 1443 114.7 64.8
P2Y12 use
Yes 2267 110.4 63.9
No 4569 113.2 63.3
ACEI/ARB use
Yes 5291 112.7 63.9
No 1545 110.9 62.3
ACEI indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor
blocker; CHD, coronary heart disease; HDL-C, high-density lipoprotein cholesterol; MI,
myocardial infarction.
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treatment target for prevention of cardiovascular events in
patients with stable CHD.
Prior to the current study, several lines of evidence
supported Lp-PLA2 activity as a risk indicator of adverse
outcomes both in patients with stable CHD and in the general
population in addition to being potentially involved in the
development of atherosclerosis and vulnerable plaque at the
tissue level.6–9,22–27 Furthermore, in 2 case–control studies,
natural deﬁciency of Lp-PLA2 activity due to carriage of the
V279F-null allele in the Lp-PLA2 gene was associated with a
lower risk of developing CHD.30 In a recent study in European
CHD patients, a single-nucleotide polymorphism of the Lp-
PLA2 gene was found to be associated with both increased Lp-
PLA2 activity in plasma and a raised risk of MI.
31 Lp-PLA2 has
also been shown to be highly concentrated in unstable and
ruptured atherosclerotic plaques and to be strongly expressed
in macrophages in lesions prone to rupture.16 Direct inhibition
of Lp-PLA2 activity prevented progression to advanced
coronary atherosclerotic lesions in diabetic and hypercholes-
terolemic swine.17 Finally, in a phase II trial, darapladib
appeared to stabilize the necrotic core size and plaque burden
in coronary atherosclerotic plaques compared with placebo18;
therefore, it was a logical hypothesis that inhibition of Lp-PLA2
activity with darapladib might lead to clinical beneﬁt, espe-
cially in patients with high Lp-PLA2 activity at baseline and/or
a pronounced reduction by the treatment.27 Nevertheless,
this current study, based on 3 to 5 years darapladib treatment
and Lp-PLA2 activity levels that were available for 14 500
patients before and during treatment and with a consistent
65% reduction of the Lp-PLA2 activity in all patient groups,
showed no associated effects of darapladib on clinical
outcomes. This ﬁnding clearly refutes any clinically important
effects of darapladib for prevention of cardiovascular events
in patients with CHD.
The current ﬁndings corroborate other studies showing
that patients with stable CHD and high Lp-PLA2 activity have a
raised risk of cardiovascular events and total mortality. The
increase in risk with Lp-PLA2 activity was not linear but was
most pronounced in the 25% of patients with the highest
levels. The increased risk associated with high Lp-PLA2
activity was independent of demographics, clinical character-
istics, and conventional biochemical risk indicators such as
dyslipidemia, dysglycemia, anemia, and renal dysfunction.
When adjusting for cardiac, inﬂammatory, and renal function
biomarkers, the independent associations between Lp-PLA2
activity and cardiovascular and total mortality and
Figure 4. Effect of darapladib compared with placebo in relation to baseline Lp-PLA2 activity (lmol/min
per liter) quartile groups concerning all outcomes. MACE speciﬁes CV death, MI, or stroke; MCE speciﬁes
coronary heart disease death, MI, or urgent coronary revascularization. Event rates are Kaplan–Meier rates.
CV indicates cardiovascular; HR, hazard ratio; Lp-PLA2, lipoprotein-associated phospholipase A2; MACE,
major adverse cardiac events; MCE, major coronary events; MI, myocardial infarction.
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hospitalization for heart failure remained, whereas the
associations with ischemic events were attenuated. Similarly,
there was no association between Lp-PLA2 activity and
cardiovascular outcomes in patients with acute coronary
syndromes, in which the majority have elevated cardiac and
inﬂammatory markers.29 Without an associated indication for
a speciﬁc treatment, it is unlikely that Lp-PLA2 activity will be
used for identiﬁcation of patients at high risk, considering the
competition with other already generally available and more
speciﬁc prognostic biomarkers. In the present study, as in a
previous study,32 there was an inverse relationship between
Lp-PLA2 activity and diabetes mellitus. In that study, diabetes
mellitus was associated with a redistribution of Lp-PLA2
activity from low- to high-density lipoprotein particles.32
These complex interactions among Lp-PLA2 activity, glucose,
and lipoprotein metabolism might need to be considered in
future studies of the importance of Lp-PLA2 activity for
cardiovascular events in different patient populations.
Conclusions
Based on the experiences from 3 to 5 years of darapladib
treatment and available Lp-PLA2 activity levels before and
during treatment in 14 500 patients with stable CHD, high
pretreatment Lp-PLA2 activity was associated with an
increased risk of cardiovascular events; however, pharmaco-
logical lowering of Lp-PLA2 activity did not signiﬁcantly reduce
cardiovascular events, regardless of the baseline level or
degree of reduction of Lp-PLA2 activity.
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Table 5. Changes in Lp-PLA2 Activity at 1 Month* Compared With Baseline in Relation to Outcomes in the Respective Placebo and
Darapladib Groups
Outcome Events
Placebo Change Darapladib Change Change From Baseline
n Mean % n Mean %
HR for 10-U
Increase (95% CI) P Value
MACE† Yes 706 10.9 5.1 646 121.7 65.5 0.99 (0.97–1.01) 0.258
No 6167 8.5 4.1 6190 111.3 63.3
MCE‡ Yes 699 9.7 4.4 614 120.4 65.1 1.00 (0.98–1.02) 0.919
No 6174 8.7 4.1 6222 111.5 63.3
Total coronary
events
Yes 1106 9.1 4.1 976 117.2 64.3 1.01 (0.99–1.02) 0.451
No 5767 8.7 4.2 5860 111.5 63.4
Cardiovascular
death
Yes 323 12.0 5.5 291 122.4 65.4 0.99 (0.96–1.01) 0.335
No 6550 8.6 4.1 6545 111.8 63.4
Myocardial
infarction
Yes 341 9.1 4.3 311 121.6 66.0 0.99 (0.97–1.02) 0.571
No 6532 8.8 4.2 6525 111.8 63.4
Stroke Yes 136 13.2 6.3 129 117.7 64.6 0.99 (0.96–1.03) 0.724
No 6737 8.7 4.1 6707 112.2 63.5
Hospitalization for
heart failure
Yes 160 10.4 4.5 136 127.5 66.8 0.97 (0.94–1.01) 0.122
No 6713 8.7 4.2 6700 112.0 63.4
All-cause mortality Yes 498 11.3 5.0 478 120.9 65.4 0.99 (0.97–1.01) 0.223
No 6375 8.6 4.1 6358 111.6 63.4
Event rates are Kaplan–Meier rates. Lp-PLA2 indicates lipoprotein-associated phospholipase A2; MACE, major adverse cardiac events; MCE, major coronary events.
*The analyses are adjusted for baseline Lp-PLA2 and stratiﬁed by randomized treatment. The changes from baseline results are identical to the Month 1 results as both are adjusted for the
baseline value.
†MACE: cardiovascular death, myocardial infarction, or stroke.
‡MCE: coronary heart disease death, myocardial infarction, or urgent coronary revascularization.
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